BIO-TECHNE Corp Share Price Nasdaq
Equities
US8783771004
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 1.16B 96.74B | Sales 2025 * | 1.25B 104B | Capitalization | 12.42B 1,037B |
---|---|---|---|---|---|
Net income 2024 * | 180M 15.02B | Net income 2025 * | 228M 19.03B | EV / Sales 2024 * | 10.9 x |
Net Debt 2024 * | 166M 13.83B | Net cash position 2025 * | 85.4M 7.13B | EV / Sales 2025 * | 9.88 x |
P/E ratio 2024 * |
70.5
x | P/E ratio 2025 * |
56.3
x | Employees | - |
Yield 2024 * |
0.41% | Yield 2025 * |
0.41% | Free-Float | 99.03% |
Latest transcript on BIO-TECHNE Corp
Managers | Title | Age | Since |
---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 57 | 30/18/30 |
James Hippel
DFI | Director of Finance/CFO | 53 | 01/14/01 |
Matthew McManus
COO | Chief Operating Officer | 55 | 08/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 01/03/01 | |
Randolph Steer
BRD | Director/Board Member | 74 | 01/90/01 |
Joseph Keegan
BRD | Director/Board Member | 71 | 26/17/26 |
1st Jan change | Capi. | |
---|---|---|
+54.35% | 59.28B | |
+41.42% | 40.94B | |
-5.34% | 40.17B | |
-5.56% | 28.69B | |
+12.01% | 26.63B | |
-20.67% | 18.89B | |
+30.01% | 12.46B | |
+26.58% | 12.26B | |
-8.67% | 11.42B |